

## Clinical criteria updates for specialty pharmacy

Published: Apr 1, 2021 - **Products & Programs** / Pharmacy

The following clinical criteria documents were endorsed at the February 19, 2021, Clinical Criteria meeting. Visit our [website](#) to access the clinical criteria information.

### **New clinical criteria effective February 25, 2021**

The following clinical criteria are new.

- ING-CC-0186 Margenza (margetuximab-cmkb)
- ING-CC-0187 Breyanzi (lisocabtagene maraleucel)

### **Revised clinical criteria effective February 25, 2021**

The following current clinical criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0028: Benlysta (belimumab)
- ING-CC-0094: Pemetrexed Agents (Alimta, Pemfexy)
- ING-CC-0107: Bevacizumab agents (Avastin, Mvasi)
- ING-CC-0167: Rituximab Agents for Oncologic Indications Step Therapy

### **Reviewed clinical criteria effective February 25, 2021**

The following current clinical criteria were reviewed and may have word changes or clarifications, but had no significant changes to the position or criteria.

- ING-CC-0002: Colony Stimulating Factor Agents

### **New clinical criteria effective March 16, 2021**

The following clinical criteria is new.

- ING-CC-0189: Amondys 45 (casimersen)
- ING-CC-0190: Nulibry (fosdenopterin)

### **Revised clinical criteria effective March 23, 2021**

The following current clinical criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0033: Xolair (omalizumab)
- ING-CC-0043: Monoclonal Antibodies to Interleukin-5
- ING-CC-0099: Abraxane (paclitaxel, protein bound)
- ING-CC-0119: Yervoy (ipilimumab)
- ING-CC-0125: Opdivo (nivolumab)
- ING-CC-0157: Padcev (enfortumab vedotin)
- ING-CC-0158: Enhertu (fam-trastuzumab deruxtecan-nxki)

### **Coding update effective March 23, 2021**

The following clinical criteria was updated with new procedure and/or diagnosis codes.

- ING-CC-0115: Kadcyla (ado-trastuzumab)

### **Reviewed clinical criteria effective March 23, 2021**

The following current clinical criteria were reviewed and may have word changes or clarifications, but had no significant changes to the position or criteria.

- ING-CC-0011: Ocrevus (ocrelizumab)
- ING-CC-0027: Denosumab Agents
- ING-CC-0085: Actimmune (interferon gamma-1B)
- ING-CC-0088: Elzonris (tagraxofusp-erzs)
- ING-CC-0089: Mozobil (plerixafor)
- ING-CC-0090: Ixempra (ixabepilone)
- ING-CC-0091: Lartruvo (olaratumab)
- ING-CC-0096: Asparagine Specific Enzymes: Oncaspar (pegaspargase), Erwinaze (asparaginase [erwinia chrysanthemi])
- ING-CC-0103: Faslodex (fulvestrant)
- ING-CC-0108: Halaven (eribulin)
- ING-CC-0109: Zaltrap (ziv-aflibercept)
- ING-CC-0110: Perjeta (pertuzumab)
- ING-CC-0112: Xofigo (Radium Ra 223 Dichloride)

- ING-CC-0113: Sylvant (siltuximab)
- ING-CC-0117: Empliciti (elotuzumab)
- ING-CC-0118: Radioimmunotherapy: Zevalin; azedra; Lutathera
- ING-CC-0120: Kyprolis (carfilzomib)
- ING-CC-0121: Gazyva (obinutuzumab)
- ING-CC-0122: Arzerra (ofatumumab)
- ING-CC-0126: Blincyto (blinatumomab)
- ING-CC-0129: Bavencio (avelumab)
- ING-CC-0130: Imfinzi (durvalumab)
- ING-CC-0131: Besponsa (inotuzumab ozogamicin)
- ING-CC-0132: Mylotarg (gemtuzumab ozogamicin)
- ING-CC-0135: Melanoma Vaccines
- ING-CC-0140: Zulresso (brexanolone)
- ING-CC-0156: Reblozyl (luspatercept)
- ING-CC-0160: Vyepi (eptinezumab-jjmr)
- ING-CC-0164: Jelmyto (mitomycin gel)

#### **New clinical criteria effective July 1, 2021**

The following clinical criteria is new.

- ING-CC-0188: Imcivree (setmelanotide)

#### **Revised clinical criteria effective July 1, 2021**

The following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

- ING-CC-0028: Benlysta (belimumab)
- ING-CC-0034: Hereditary Angioedema Agents
- ING-CC-0043: Monoclonal Antibodies to Interleukin-5
- ING-CC-0067: Prostacyclin Infusion and Inhalation Therapy
- ING-CC-0075: Rituxan (rituximab) for Non-Oncologic Indications
- ING-CC-0086: Spravato (esketamine) Nasal Spray
- ING-CC-0094: Pemetrexed Agents (Alimta, Pemfexy)
- ING-CC-0115: Kadcyla (ado-trastuzumab)
- ING-CC-0119: Yervoy (ipilimumab)

- ING-CC-0123: Cyramza (ramucirumab)
- ING-CC-0125: Opdivo (nivolumab)
- ING-CC-0157: Padcev (enfortumab vedotin)

1087-0421-PN-NE

**URL:** <https://providernews.anthem.com/maine/article/clinical-criteria-updates-for-specialty-pharmacy-52>

**Featured In:**

April 2021 Anthem Connecticut Provider News, April 2021 Anthem New Hampshire Provider News, April 2021 Anthem Maine Provider News

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

---